Xiaomin Chen successfully launched Amador Bioscience’s Hangzhou, China location in 2018. Today, as Chief Operations Officer, Xiaomin continues to grow and establish Amador's global presence by implementing local strategies and evaluating key company investments.

Before joining Amador, Xiaomin held positions of increasing responsibility at Novartis, including roles that involved strategic planning and submission of multiple INDs for biologics. She also spent time as a clinical pharmacology scientist at Exelixis and at Medimmune, a wholly-owned subsidiary of Astra-Zeneca.

Xiaomin holds a Bachelor of Science with a double major in Pharmaceutics and Biomedical Pharmacology, and a Master of Science in Pharmaceutical Science from the SUNY University at Buffalo. She also holds a Master of Business Administration from the New York University Leonard N. Stern School of Business.